Xoma reported $110.71M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Agenus USD 133.44M 514K Dec/2025
Agios Pharmaceuticals USD 942.05M 91.06M Dec/2025
Ardelyx USD 382.32M 14.33M Dec/2025
aTyr Pharma USD 245.8M 152.79M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Celldex Therapeutics USD 534.66M 69.68M Dec/2025
Curis USD 6.92M 7.5M Dec/2025
Eli Lilly USD 55.63B 6.44B Dec/2025
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Incyte USD 5.02B 746.01M Dec/2025
MacroGenics USD 219.94M 12.15M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Prothena USD 315.19M 24.78M Dec/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Xoma USD 110.71M 5.78M Sep/2025